Literature DB >> 24307778

Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Marija Zeremski1, Jon E Zibbell, Anthony D Martinez, Steven Kritz, Bryce D Smith, Andrew H Talal.   

Abstract

Despite a high prevalence of hepatitis C virus (HCV) infection, the vast majority of persons who inject drugs (PWID) have not engaged in HCV care due to a large number of obstacles. Education about the infection among both PWID and providers remains an important challenge as does discrimination faced by PWID in conventional health care settings. Many providers also remain hesitant to prescribe antiviral therapy due to concerns about adherence and relapse to drug use resulting in reinfection. Presently, however, as a result of improvements in treatment efficacy combined with professional society and government endorsement of HCV treatment for PWID, a pressing need exists to develop strategies to engage these individuals into HCV care. In this article, we propose several strategies that can be pursued in an attempt to engage PWID into HCV management. We advocate that multidisciplinary approaches that utilize health care practitioners from a wide range of specialties, as well as co-localization of medical services, are strategies likely to result in increased numbers of PWID entering into HCV management. Pursuit of HCV therapy after stabilization through drug treatment is an additional strategy likely to increase PWID engagement into HCV care. The full impact of direct acting antivirals for HCV will only be realized if innovative approaches are pursued to engage all HCV infected individuals into treatment.

Entities:  

Keywords:  Hepatitis C virus coinfection; Human immunodeficiency virus; Obstacles to treatment; Persons who inject drugs; Treatment of hepatitis C; Viral infection

Mesh:

Substances:

Year:  2013        PMID: 24307778      PMCID: PMC3848132          DOI: 10.3748/wjg.v19.i44.7846

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.

Authors:  Shruti H Mehta; Gregory M Lucas; Lisa B Mirel; Michael Torbenson; Yvonne Higgins; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  AIDS       Date:  2006-11-28       Impact factor: 4.177

2.  Referral for chronic hepatitis C treatment from a drug dependency treatment setting.

Authors:  Richard Hallinan; Andrew Byrne; Kingsley Agho; Gregory J Dore
Journal:  Drug Alcohol Depend       Date:  2006-10-25       Impact factor: 4.492

3.  A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.

Authors:  Donna M Evon; Kelly Simpson; Scott Kixmiller; Joseph Galanko; Karen Dougherty; Carol Golin; Michael W Fried
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

Review 4.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

5.  Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.

Authors:  Alain H Litwin; Irene Soloway; Marc N Gourevitch
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

6.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

7.  Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.

Authors:  Aud L Krook; Dorthe Stokka; Bernt Heger; Egil Nygaard
Journal:  Eur Addict Res       Date:  2007       Impact factor: 3.015

8.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

9.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

View more
  34 in total

1.  Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.

Authors:  Natalie A Blackburn; Rajiv C Patel; Jon E Zibbell
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

2.  High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.

Authors:  Basmattee Boodram; Anna L Hotton; Louis Shekhtman; Alexander Gutfraind; Harel Dahari
Journal:  J Urban Health       Date:  2018-02       Impact factor: 3.671

Review 3.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

Review 4.  A Guide to the Economics of Hepatitis C Virus Cure in 2017.

Authors:  Benjamin P Linas; Shayla Nolen
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

Review 5.  Hepatitis C: Treatment of difficult to treat patients.

Authors:  Eric G Hilgenfeldt; Alex Schlachterman; Roberto J Firpi
Journal:  World J Hepatol       Date:  2015-07-28

6.  Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Authors:  Marija Zeremski; Rositsa B Dimova; Roberto Zavala; Steven Kritz; Melissa Lin; Bryce D Smith; Jon E Zibbell; Andrew H Talal
Journal:  J Addict Med       Date:  2014 Jul-Aug       Impact factor: 3.702

7.  Public health clinic-based hepatitis C testing and linkage to care in Baltimore.

Authors:  O Falade-Nwulia; S H Mehta; J Lasola; C Latkin; A Niculescu; C O'Connor; P Chaulk; K Ghanem; K R Page; M S Sulkowski; D L Thomas
Journal:  J Viral Hepat       Date:  2016-02-03       Impact factor: 3.728

8.  Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.

Authors:  Maria A Corcorran; Judith I Tsui; John D Scott; Julia C Dombrowski; Sara N Glick
Journal:  Drug Alcohol Depend       Date:  2021-01-11       Impact factor: 4.492

9.  "Health Is on the Back Burner:" Multilevel Barriers and Facilitators to Primary Care Among People Who Inject Drugs.

Authors:  Delia Motavalli; Jessica L Taylor; Ellen Childs; Pablo K Valente; Peter Salhaney; Jennifer Olson; Dea L Biancarelli; Alberto Edeza; Joel J Earlywine; Brandon D L Marshall; Mari-Lynn Drainoni; Matthew J Mimiaga; Katie B Biello; Angela R Bazzi
Journal:  J Gen Intern Med       Date:  2020-09-11       Impact factor: 5.128

10.  An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.

Authors:  Nyashadzaishe Mafirakureva; Jack Stone; Hannah Fraser; Yvonne Nzomukunda; Aron Maina; Angela W Thiong'o; Kibango Walter Kizito; Esther W K Mucara; C Inés González Diaz; Helgar Musyoki; Bernard Mundia; Peter Cherutich; Mercy Nyakowa; John Lizcano; Nok Chhun; Ann Kurth; Matthew J Akiyama; Wanjiru Waruiru; Parinita Bhattacharjee; Charles Cleland; Dmytro Donchuk; Niklas Luhmann; Anne Loarec; David Maman; Josephine Walker; Peter Vickerman
Journal:  Addiction       Date:  2021-07-28       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.